



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Total Artificial Hearts and Implantable Ventricular Assist Devices

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 280

BCBSA Reference Number: 7.03.11 (For Plan internal use only)

NCD/LCD: N/A

Related Policies

- Heart/Lung Transplant, #[269](#)
- Heart Transplant, #[197](#)
- Extracorporeal Membrane Oxygenation, #[726](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Destination Therapy

Implantable ventricular assist devices (VADs) with FDA approval or clearance may be considered **MEDICALLY NECESSARY** as destination therapy with end-stage heart failure adult individuals who meet the following criteria:

- New York Heart Association (NYHA) Class III heart failure with dyspnea upon mild physical activity or NYHA Class IV;
- Left ventricular ejection fraction $\leq 25\%$;
- Inotrope-dependent; OR cardiac index < 2.2 liters/min/m², while not on inotropes and also meeting **one** of the following:
 - On optimal medical management, based on current heart failure practice guidelines for at least 45 of the last 60 days and are failing to respond **OR**
 - Advanced heart failure for at least 14 days and dependent on intra-aortic balloon pump for ≥ 7 days.

Bridge to Transplantation

Implantable ventricular assist devices (VADs) with FDA approval or clearance may be considered **MEDICALLY NECESSARY** as a bridge to heart transplantation for individuals who are:

- Currently listed as heart transplantation candidates and not expected to survive until a donor heart can be obtained, **OR**
- Are undergoing evaluation to determine candidacy for heart transplantation.

Implantable (VADs) with FDA approval or clearance, including humanitarian device exemptions, may be considered **MEDICALLY NECESSARY** as a bridge to heart transplantation in children 16 years old or younger who are:

- Currently listed as heart transplantation candidates and not expected to survive until a donor heart can be obtained, **OR**
- Are undergoing evaluation to determine candidacy for heart transplantation.

Total artificial hearts (TAHs) with FDA-approved devices may be considered **MEDICALLY NECESSARY** as a bridge to heart transplantation for individuals with biventricular failure who:

- Have no other reasonable medical or surgical treatment options, are ineligible for other univentricular or biventricular support devices, and are currently listed as heart transplantation candidates, **OR**
- Have no other reasonable medical or surgical treatment options, are ineligible for other univentricular or biventricular support devices, are undergoing evaluation to determine candidacy for heart transplantation, and not expected to survive until a donor heart can be obtained.

Postcardiotomy Setting/Bridge to Recovery

Implantable VADs with FDA approval approval or clearance may be considered **MEDICALLY NECESSARY** in the postcardiotomy setting in individuals who are unable to be weaned off cardiopulmonary bypass.

Other Indications

Other applications of ventricular assist devices (VADs) or total artificial hearts (TAHs) are considered **INVESTIGATIONAL**, including, but not limited to, the use of TAHs as destination therapy.

The use of non-FDA approved or cleared implantable VADs or TAHs is considered **INVESTIGATIONAL**.

Percutaneous VADs are considered **INVESTIGATIONAL** for all indications.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This procedure is performed in the inpatient setting.
Commercial PPO and Indemnity	This procedure is performed in the inpatient setting.
Medicare HMO BlueSM	This procedure is performed in the inpatient setting.
Medicare PPO BlueSM	This procedure is performed in the inpatient setting.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
33975	Insertion of ventricular assist device; extracorporeal, single ventricle
33976	Insertion of ventricular assist device; extracorporeal, biventricular
33977	Removal of ventricular assist device; extracorporeal, single ventricle
33978	Removal of ventricular assist device; extracorporeal, biventricular
33979	Insertion of ventricular assist device, implantable intracorporeal, single ventricle
33980	Removal of ventricular assist device, implantable intracorporeal, single ventricular
33981	Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s), single or each pump
33982	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass
33983	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass
33990	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; left heart, arterial access only
33991	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; left heart, both arterial and venous access, with transeptal puncture
33992	Removal of percutaneous left heart ventricular assist device, arterial or arterial and venous cannula(s), at separate and distinct session from insertion
33993	Repositioning of percutaneous right or left heart ventricular assist device with imaging guidance at separate and distinct session from insertion
33995	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; right heart, venous access only
33997	Removal of percutaneous right heart ventricular assist device, venous cannula, at separate and distinct session from insertion
33927	Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy
33928	Removal and replacement of total replacement heart system (artificial heart)
33929	Removal of a total replacement heart system (artificial heart) for heart transplantation (List separately in addition to code for primary procedure)
93750	Interrogation of ventricular assist device, in person, with physician analysis of device parameters (eg, drivelines, alarms, power surges), review of device function (eg, flow volume status, septum status, recovery), with programming, if performed, and report

HCPCS Codes

HCPCS codes:	Code Description
Q0477	Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0478	Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
Q0479	Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0480	Driver for use with pneumatic ventricular assist device, replacement only
Q0481	Microprocessor control unit for use with electric ventricular assist device, replacement only
Q0482	Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only
Q0483	Monitor/display module for use with electric ventricular assist device, replacement only

Q0484	Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0485	Monitor control cable for use with electric ventricular assist device, replacement only
Q0486	Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only
Q0487	Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only
Q0488	Power pack base for use with electric ventricular assist device, replacement only
Q0489	Power pack base for use with electric/pneumatic ventricular assist device, replacement only
Q0490	Emergency power source for use with electric ventricular assist device, replacement only
Q0491	Emergency power source for use with electric/pneumatic ventricular assist device, replacement only
Q0492	Emergency power supply cable for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0493	Emergency power supply cable for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0494	Emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0495	Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0496	Battery for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0497	Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0498	Holster for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0499	Belt/vest for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0500	Filters for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0501	Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0502	Mobility cart for pneumatic ventricular assist device, replacement only
Q0503	Battery for pneumatic ventricular assist device, replacement only, each
Q0504	Power adapter for pneumatic ventricular assist device, replacement only, vehicle type
Q0506	Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only

ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
02RK0JZ	Replacement of Right Ventricle with Synthetic Substitute, Open Approach
02HA0QZ	Insertion of Implantable Heart Assist System into Heart, Open Approach
02HA0RS	Insertion of Biventricular External Heart Assist System into Heart, Open Approach
02HA0RZ	Insertion of External Heart Assist System into Heart, Open Approach
02HA3QZ	Insertion of Implantable Heart Assist System into Heart, Percutaneous Approach
02HA3RS	Insertion of Biventricular External Heart Assist System into Heart, Percutaneous Approach
02HA3RZ	Insertion of External Heart Assist System into Heart, Percutaneous Approach
02HA4QZ	Insertion of Implantable Heart Assist System into Heart, Percutaneous Endoscopic Approach

02HA4RS	Insertion of Biventricular External Heart Assist System into Heart, Percutaneous Endoscopic Approach
02HA4RZ	Insertion of External Heart Assist System into Heart, Percutaneous Endoscopic Approach
02RK4JZ	Replacement of Right Ventricle with Synthetic Substitute, Percutaneous Endoscopic Approach
02RL0JZ	Replacement of Left Ventricle with Synthetic Substitute, Open Approach
02RL4JZ	Replacement of Left Ventricle with Synthetic Substitute, Percutaneous Endoscopic Approach
02UA0JZ	Supplement Heart with Synthetic Substitute, Open Approach
02UA3JZ	Supplement Heart with Synthetic Substitute, Percutaneous Approach
02UA4JZ	Supplement Heart with Synthetic Substitute, Percutaneous Endoscopic Approach
02WA0JZ	Revision of Synthetic Substitute in Heart, Open Approach
02WA0QZ	Revision of Implantable Heart Assist System in Heart, Open Approach
02WA3QZ	Revision of Implantable Heart Assist System in Heart, Percutaneous Approach
02WA3RZ	Revision of External Heart Assist System in Heart, Percutaneous Approach
02WA4QZ	Revision of Implantable Heart Assist System in Heart, Percutaneous Endoscopic Approach
5A02116	Assistance with Cardiac Output using Other Pump, Intermittent
5A02216	Assistance with Cardiac Output using Other Pump, Continuous

Description

Heart Failure

According to a 2022 report from the American Heart Association and based on data collected from 2015 to 2018, roughly 6 million Americans ages 20 years or older had heart failure during that time frame.¹ Prevalence of heart failure is projected to affect more than 8 million people 18 years of age and older by the year 2030. Between 2015 and 2018, the prevalence of heart failure was highest in non-Hispanic Black males. Based on data from the Multi-Ethnic Study of Atherosclerosis (MESA), in those without baseline cardiovascular disease, Black individuals had the highest risk of developing heart failure (4.6 per 1000 person-years), followed by Hispanic (3.5 per 1000 person-years), White (2.4 per 1000 person-years), and Chinese individuals (1.0 per 1000 person-years).² Similar findings were demonstrated in the Atherosclerosis Risk in Communities (ARIC) Community Surveillance data, in which Black men and women had the highest burden of new-onset heart failure cases and the highest-age adjusted 30-day case fatality rate in comparison to White men and women. Higher risk reflected differential prevalence of hypertension, diabetes, and low socio-economic status.

Heart failure may be the consequence of a number of etiologies, including ischemic heart disease, cardiomyopathy, congenital heart defects, or rejection of a heart transplant. The reduction of cardiac output is considered to be severe when systemic circulation cannot meet the body's needs under minimal exertion. Heart transplantation improves quality of life and has survival rates at 1, 3, and 5 years of about 91%, 85%, and 78%, respectively.³ The number of candidates for transplants exceeds the supply of donor organs; thus the interest in the development of mechanical devices.

Devices and Regulatory Status

A number of implantable ventricular assist devices (VADs) and artificial heart systems have been U.S. Food and Drug Administration (FDA) approved through a Humanitarian Device Exemption, 510(k), or premarket approval regulatory pathway. This section discusses currently marketed devices.

FDA maintains a list of recent device recalls at <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls>.

Ventricular Assist Devices

Implantable VADs are attached to the native heart, which may have enough residual capacity to withstand a device failure in the short term. In reversible heart failure conditions, the native heart may regain some

function, and weaning and explanting of the mechanical support system after months of use has been described. VADs can be classified as internal or external, electrically or pneumatically powered, and pulsatile or continuous-flow. Initial devices were pulsatile, mimicking the action of a beating heart. More recent devices may use a pump, which provides continuous flow. Continuous devices may move blood in a rotary or axial flow.

Surgically implanted VADs represent a method of providing mechanical circulatory support for patients not expected to survive until a donor heart becomes available for transplant or for whom transplantation is contraindicated or unavailable. VADs are most commonly used to support the left ventricle but right ventricular and biventricular devices may be used. The device is larger than most native hearts, and therefore the size of the patient is an important consideration; the pump may be implanted in the thorax or abdomen or remain external to the body. Inflow to the device is attached to the apex of the failed ventricle, while outflow is attached to the corresponding great artery (aorta for the left ventricle, a pulmonary artery for the right ventricle). A small portion of the ventricular wall is removed for insertion of the outflow tube; extensive cardiomy affecting the ventricular wall may preclude VAD use.

The intent of treatment may evolve over the course of treatment; for example, there is not necessarily a strict delineation between bridge to transplant and destination therapy, and transplant eligibility can change.

Table 1 lists the VADs currently available in the US. The HeartWare VAD System was discontinued in June 2021 due to evidence from observational studies demonstrating a higher frequency of neurological adverse events and mortality with the system compared to other commercially available left VADs.

Table 1. Available Ventricular Assist Devices

Device	Manufacturer	Approval Date	FDA Clearance	PMA, HDE or 510(k) No.	Indication
Thoratec IVAD	Thoratec	Aug 2004	PMA Supp	P870072	Bridge to transplant and postcardiotomy
DeBakey VAD Child	MicroMed	Feb 2004	HDE	H030003	Bridge to transplant in children 5-16 y
HeartMate II	Thoratec	Apr 2008	PMA	P060040	Bridge to transplant and destination
CentriMag	Thoratec	Dec 2019	PMA	P170038	Postcardiotomy, bridge to decision
Berlin Heart EXCOR Pediatric VAD	Berlin	Jun 2017	PMA	P160035	Bridge to transplant
HeartMate 3 Left Ventricular Assist System	Thoratec	Aug 2017 Oct 2018	PMA PMA	P160054 P160054/S008	Bridge to transplant Destination

FDA: U.S. Food and Drug Administration; HDE: humanitarian device exemption; PMA: premarket approval; VAD: ventricular assist device.

Total Artificial Heart

The total artificial heart (TAH) is a biventricular device that completely replaces the function of the diseased heart. An internal battery requires frequent recharging from an external power source. Many systems use a percutaneous power line, but a transcutaneous power-transfer coil allows for a system without lines traversing the skin, possibly reducing the risk of infection. Because the native heart must be removed, failure of the device is synonymous with cardiac death.

Currently the Syncardia Temporary Total Artificial Heart (Syncardia Systems) is the only Total Artificial Heart available in the US (Table 2). The AbioCor Total Artificial Heart was FDA approved under the Humanitarian Device Exemption program in 2006, but is no longer being marketed or in development.

Table 2. Available Total Artificial Heart

Device	Manufacturer	Approval Date	FDA Clearance	PMA No.	Indication
SynCardia Temporary Total Artificial Heart (Formerly CardioWest Total Artificial Heart and Jarvik Total Artificial Heart)	SynCardia Systems	2004	510(k)	P030011	Bridge to transplant in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure

FDA: U.S. Food and Drug Administration; PMA: premarket approval.

Percutaneous Ventricular Assist Devices

Some circulatory assist devices are placed percutaneously (i.e., are not implanted). They may be referred to as percutaneous VADs (pVADs). Two different pVADs have been developed, the TandemHeart and the Impella device (Table 3). In the TandemHeart System, a catheter is introduced through the femoral vein and passed into the left atrium via transseptal puncture. Oxygenated blood is then pumped from the left atrium into the arterial system via the femoral artery. The Impella device is introduced through a femoral artery catheter. In this device, a small pump is contained within the catheter placed into the left ventricle. Blood is pumped from the left ventricle, through the device, and into the ascending aorta. Devices in which most of the system's components are external to the body are for short-term use (6 hours to 14 days) only, due to the increased risk of infection and need for careful, in-hospital monitoring. Adverse events associated with pVAD include access site complications such as bleeding, aneurysms, or leg ischemia. Cardiovascular complications can also occur, such as perforation, myocardial infarction, stroke, and arrhythmias.

Table 3. Available Percutaneous Ventricular Assist Devices

Device	Manufacturer	Approval Date	FDA Clearance	PMA, 510(k) No.	Indication
TandemHeart	Cardiac Assist	Sep 2011	510(k)	K110493	Temporary left ventricular bypass of ≤6 h
Impella Recover LP 2.5	Abiomed	May 2008	510(k)	K063723	Partial circulatory support using extracorporeal bypass control unit for ≤6 h
Impella 2.5 System	Abiomed	Mar 2015	PMA	P140003	Temporary ventricular support for ≤6 h

FDA: U.S. Food and Drug Administration; PMA: premarket approval.

Summary

Description

A ventricular assist device (VAD) is mechanical support attached to the native heart and vessels to augment cardiac output. The total artificial heart (TAH) replaces the native ventricles and is attached to the pulmonary artery and aorta; the native heart is typically removed. Both the VAD and TAH may be used as a bridge to heart transplantation or as destination therapy. The VAD has also been used as a bridge to recovery in patients with reversible conditions affecting cardiac output.

Summary of Evidence

Ventricular Assist Device

For individuals who have end-stage heart failure who receive a ventricular assist device (VAD) as a bridge to transplant, the evidence includes a randomized controlled trial (RCT) single-arm trials, and observational studies. Relevant outcomes are overall survival (OS) symptoms, functional outcomes, quality of life (QOL) and treatment-related mortality and morbidity. There is a substantial body of evidence from clinical trials and observational studies supporting implantable VADs as a bridge to transplant in patients

with end-stage heart failure, possibly reducing mortality as well as improving QOL. These studies have reported that substantial numbers of patients have survived to transplant in situations in which survival would not be otherwise expected. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have end-stage heart failure who receive a VAD as destination therapy, the evidence includes RCTs and multiple single-arm studies. Relevant outcomes are OS, symptoms, functional outcomes, QOL, and treatment-related mortality and morbidity. A well-designed trial with 2 years of follow-up data has demonstrated an advantage of implantable VADs as destination therapy for patients ineligible for a heart transplant. Despite an increase in adverse events, both mortality and QOL appear to be improved for these patients. A more recent trial comparing VADs has broader inclusion criteria and supports that criteria move away from use of transplant ineligibility, as treatment may evolve over the course of treatment. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Total Artificial Heart

For individuals who have end-stage heart failure who receive a total artificial heart (TAH) as a bridge to transplant, the evidence includes case series. Relevant outcomes are OS, symptoms, functional outcomes, QOL, and treatment-related mortality and morbidity. Compared with VADs, the evidence for TAHs in these settings is less robust. However, given the lack of medical or surgical options for these patients and the evidence case series provide, TAH is likely to improve outcomes for a carefully selected population with end-stage biventricular heart failure awaiting transplant who are not appropriate candidates for a left VAD. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have end-stage heart failure who receive a TAH as destination therapy, the evidence includes 2 case series. Relevant outcomes are OS, symptoms, functional outcomes, QOL, and treatment-related mortality and morbidity. The body of evidence for TAHs as destination therapy is too limited to draw conclusions. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Percutaneous Ventricular Assist Device

For individuals with cardiogenic shock who receive a percutaneous VAD (pVAD) the evidence includes RCTs, observational studies, and a systematic review. Relevant outcomes are OS, symptoms, morbid events, functional outcomes, QOL, and treatment-related mortality and morbidity. Four RCTs of pVAD versus intra-aortic balloon pump (IABP) for patients in cardiogenic shock failed to demonstrate a mortality benefit and reported higher complication rates with pVAD use. Comparative observational studies and a long-term follow-up study were consistent with the RCT evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who undergo high-risk cardiac procedures who receive a pVAD, the evidence includes RCTs, observational studies, and systematic reviews of these trials. Relevant outcomes are OS, symptoms, morbid events, functional outcomes, QOL, and treatment-related mortality and morbidity. Randomized controlled trials, controlled and uncontrolled observational studies, and systematic reviews of these studies have not demonstrated a benefit of pVAD used as ancillary support for patients undergoing high-risk cardiac procedures. Additionally, 2 nonrandomized studies have compared ventricular tachycardia (VT) ablation with pVAD or IABP. Both studies demonstrated that patients who had pVAD support spent less time in unstable VT than patients without pVAD support. However, the current evidence does not support conclusions about the use of pVAD for VT ablation. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with cardiogenic shock refractory to IABP therapy who receive a pVAD, the evidence includes case series. Relevant outcomes are OS, symptoms, morbid events, functional outcomes, QOL, and treatment-related mortality and morbidity. Case series of patients with cardiogenic shock refractory to IABP have reported improved hemodynamic parameters following pVAD placement. However, these uncontrolled series do not provide evidence that pVADs improve mortality, and high rates of complications

have been reported with pVAD use. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
10/2023	Annual policy review. References added. Editorial refinements to policy statements for clarity; intent unchanged.
10/2022	Annual policy review. References added and updated. Minor editorial refinements to policy statements; intent unchanged.
10/2021	Annual policy review. Evidence review revised substantially to increase clarity. Policy statement revised to remove outdated eligibility criteria, but intent unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
1/2021	Clarified coding information.
10/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
10/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
10/2018	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2018	Clarified coding information.
10/2017	Annual policy review. Policy statements were reordered; wording of statements unchanged.
10/2016	Annual policy review. New references added.
7/2015	Annual policy review. New references added.
7/2014	Annual policy review. New references added. Coding information clarified.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015. Coding information clarified.
8/2013	Annual policy review. Policy statement on children amended; age range changed from 5-16 to 0-16. Effective 8/1/2013.
1/2013	Updated to add new CPT codes 33990-33993.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
4/2011	Reviewed - Medical Policy Group - Cardiology and Pulmonology. No changes to policy statements.
1/2011	New policy posted 1/2011. Same information removed from policy #388, Total Artificial Hearts and Ventricular Assist Devices.
4/2010	Reviewed - Medical Policy Group - Cardiology. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. Feb 22 2022; 145(8): e153-e639. PMID 35078371
2. Lewsey SC, Breathett K. Racial and ethnic disparities in heart failure: current state and future directions. *Curr Opin Cardiol*. May 01 2021; 36(3): 320-328. PMID 33741769

3. Organ Procurement and Transplantation Network. Heart Kaplan-Meier Patient Survival Rates For Transplants Performed : 2008 - 2015. 2018; <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#>. Accessed June 20, 2023.
4. TEC Assessment Program. Ventricular assist devices in bridging to heart transplantation. 1996; Volume 11; Tab 26.
5. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. *N Engl J Med*. Nov 19 1998; 339(21): 1522-33. PMID 9819452
6. Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. *N Engl J Med*. Apr 25 2019; 380(17): 1618-1627. PMID 30883052
7. Colombo PC, Mehra MR, Goldstein DJ, et al. Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study. *Circulation*. Jan 08 2019; 139(2): 155-168. PMID 30586698
8. Cowger JA, Naka Y, Aaronson KD, et al. Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: A call for new metrics for left ventricular assist device patients. *J Heart Lung Transplant*. Jan 2018; 37(1): 15-24. PMID 29153637
9. Goldstein DJ, Naka Y, Horstmanshof D, et al. Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial. *JAMA Cardiol*. Apr 01 2020; 5(4): 411-419. PMID 31939996
10. Slaughter MS, Pagani FD, McGee EC, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. *J Heart Lung Transplant*. Jul 2013; 32(7): 675-83. PMID 23796152
11. Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. *J Am Coll Cardiol*. Mar 22 2011; 57(12): 1375-82. PMID 21414534
12. Aaronson KD, Eppinger MJ, Dyke DB, et al. Left ventricular assist device therapy improves utilization of donor hearts. *J Am Coll Cardiol*. Apr 17 2002; 39(8): 1247-54. PMID 11955839
13. Frazier OH, Gemmato C, Myers TJ, et al. Initial clinical experience with the HeartMate II axial-flow left ventricular assist device. *Tex Heart Inst J*. 2007; 34(3): 275-81. PMID 17948075
14. John R, Kamdar F, Liao K, et al. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. *Ann Thorac Surg*. Oct 2008; 86(4): 1227-34; discussion 1234-5. PMID 18805167
15. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. *N Engl J Med*. Aug 30 2007; 357(9): 885-96. PMID 17761592
16. Patel ND, Weiss ES, Schaffer J, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. *Ann Thorac Surg*. Sep 2008; 86(3): 832-40; discussion 832-40. PMID 18721570
17. Strüber M, Sander K, Lahpor J, et al. HeartMate II left ventricular assist device; early European experience. *Eur J Cardiothorac Surg*. Aug 2008; 34(2): 289-94. PMID 18571932
18. Kirklin JK, Naftel DC, Stevenson LW, et al. INTERMACS database for durable devices for circulatory support: first annual report. *J Heart Lung Transplant*. Oct 2008; 27(10): 1065-72. PMID 18926395
19. Aissaoui N, Morshuis M, Maoulida H, et al. Management of end-stage heart failure patients with or without ventricular assist device: an observational comparison of clinical and economic outcomes. *Eur J Cardiothorac Surg*. Jan 01 2018; 53(1): 170-177. PMID 28950304
20. Schmitto JD, Pya Y, Zimpfer D, et al. Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study. *Eur J Heart Fail*. Jan 2019; 21(1): 90-97. PMID 30052304
21. Gustafsson F, Shaw S, Lavee J, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. *Eur Heart J*. Oct 01 2018; 39(37): 3454-3460. PMID 30165521
22. Pagani FD, Mehra MR, Cowger JA, et al. Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices - The CLEAR-LVAD study. *J Heart Lung Transplant*. May 2021; 40(5): 323-333. PMID 33744086
23. Mehra MR, Cleveland JC, Uriel N, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. *Eur J Heart Fail*. Aug 2021; 23(8): 1392-1400. PMID 33932272

24. TEC Assessment Program. Left ventricular assist devices as destination therapy for end-stage heart failure. 2002;Volume 17;Tab 19.
25. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med*. Nov 15 2001; 345(20): 1435-43. PMID 11794191
26. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. *J Thorac Cardiovasc Surg*. Jan 2005; 129(1): 9-17. PMID 15632819
27. Long JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. *Congest Heart Fail*. 2005; 11(3): 133-8. PMID 15947534
28. Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. *N Engl J Med*. Feb 02 2017; 376(5): 451-460. PMID 28146651
29. Estep JD, Starling RC, Horstmanshof DA, et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study. *J Am Coll Cardiol*. Oct 20 2015; 66(16): 1747-1761. PMID 26483097
30. Starling RC, Estep JD, Horstmanshof DA, et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. *JACC Heart Fail*. Jul 2017; 5(7): 518-527. PMID 28396040
31. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). *J Am Coll Cardiol*. May 06 2014; 63(17): 1751-7. PMID 24613333
32. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. *J Am Coll Cardiol*. Aug 21 2007; 50(8): 741-7. PMID 17707178
33. Arnold SV, Jones PG, Allen LA, et al. Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy: Results From the INTERMACS Registry. *Circ Heart Fail*. Aug 2016; 9(8). PMID 27507111
34. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. *JAMA*. Sep 27 2022; 328(12): 1233-1242. PMID 36074476
35. Acharya D, Loyaga-Rendon RY, Pamboukian SV, et al. Ventricular Assist Device in Acute Myocardial Infarction. *J Am Coll Cardiol*. Apr 26 2016; 67(16): 1871-80. PMID 27102502
36. Wever-Pinzon O, Drakos SG, McKellar SH, et al. Cardiac Recovery During Long-Term Left Ventricular Assist Device Support. *J Am Coll Cardiol*. Oct 04 2016; 68(14): 1540-53. PMID 27687196
37. Topkara VK, Garan AR, Fine B, et al. Myocardial Recovery in Patients Receiving Contemporary Left Ventricular Assist Devices: Results From the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). *Circ Heart Fail*. Jul 2016; 9(7). PMID 27402861
38. Maybaum S, Mancini D, Xydas S, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. *Circulation*. May 15 2007; 115(19): 2497-505. PMID 17485581
39. Agrawal S, Garg L, Shah M, et al. Thirty-Day Readmissions After Left Ventricular Assist Device Implantation in the United States: Insights From the Nationwide Readmissions Database. *Circ Heart Fail*. Mar 2018; 11(3): e004628. PMID 29519902
40. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J*. Oct 2008; 29(19): 2388-442. PMID 18799522
41. Bulic A, Maeda K, Zhang Y, et al. Functional status of United States children supported with a left ventricular assist device at heart transplantation. *J Heart Lung Transplant*. Aug 2017; 36(8): 890-896. PMID 28363739
42. Wehman B, Stafford KA, Bittle GJ, et al. Modern Outcomes of Mechanical Circulatory Support as a Bridge to Pediatric Heart Transplantation. *Ann Thorac Surg*. Jun 2016; 101(6): 2321-7. PMID 26912304
43. Fraser CD, Jaquiss RD, Rosenthal DN, et al. Prospective trial of a pediatric ventricular assist device. *N Engl J Med*. Aug 09 2012; 367(6): 532-41. PMID 22873533

44. Blume ED, Rosenthal DN, Rossano JW, et al. Outcomes of children implanted with ventricular assist devices in the United States: First analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS). *J Heart Lung Transplant*. May 2016; 35(5): 578-84. PMID 27009673
45. Almond CS, Morales DL, Blackstone EH, et al. Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. *Circulation*. Apr 23 2013; 127(16): 1702-11. PMID 23538380
46. Jordan LC, Ichord RN, Reinhartz O, et al. Neurological complications and outcomes in the Berlin Heart EXCOR® pediatric investigational device exemption trial. *J Am Heart Assoc*. Jan 22 2015; 4(1): e001429. PMID 25613996
47. Chen S, Lin A, Liu E, et al. Outpatient Outcomes of Pediatric Patients with Left Ventricular Assist Devices. *ASAIO J*. 2016; 62(2): 163-8. PMID 26720740
48. Conway J, Al-Aklabi M, Granoski D, et al. Supporting pediatric patients with short-term continuous-flow devices. *J Heart Lung Transplant*. May 2016; 35(5): 603-9. PMID 27009672
49. Frazier OH, Rose EA, McCarthy P, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. *Ann Surg*. Sep 1995; 222(3): 327-36; discussion 336-8. PMID 7677462
50. Bank AJ, Mir SH, Nguyen DQ, et al. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. *Ann Thorac Surg*. May 2000; 69(5): 1369-74; discussion 1375. PMID 10881807
51. Shuhaiber JH, Hur K, Gibbons R. The influence of preoperative use of ventricular assist devices on survival after heart transplantation: propensity score matched analysis. *BMJ*. Feb 10 2010; 340: c392. PMID 20147346
52. Alba AC, McDonald M, Rao V, et al. The effect of ventricular assist devices on long-term post-transplant outcomes: a systematic review of observational studies. *Eur J Heart Fail*. Jul 2011; 13(7): 785-95. PMID 21551162
53. Deo SV, Sung K, Daly RC, et al. Cardiac transplantation after bridged therapy with continuous flow left ventricular assist devices. *Heart Lung Circ*. Mar 2014; 23(3): 224-8. PMID 23954004
54. Grimm JC, Sciortino CM, Magruder JT, et al. Outcomes in Patients Bridged With Univentricular and Biventricular Devices in the Modern Era of Heart Transplantation. *Ann Thorac Surg*. Jul 2016; 102(1): 102-8. PMID 27068177
55. Davies RR, Russo MJ, Hong KN, et al. The use of mechanical circulatory support as a bridge to transplantation in pediatric patients: an analysis of the United Network for Organ Sharing database. *J Thorac Cardiovasc Surg*. Feb 2008; 135(2): 421-7, 427.e1. PMID 18242279
56. Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. *N Engl J Med*. Aug 26 2004; 351(9): 859-67. PMID 15329423
57. Copeland JG, Copeland H, Gustafson M, et al. Experience with more than 100 total artificial heart implants. *J Thorac Cardiovasc Surg*. Mar 2012; 143(3): 727-34. PMID 22245242
58. Food and Drug Administration. Summary of Safety and Probable Benefit - H040006: AbioCor Implantable Replacement Heart. 2006; https://www.accessdata.fda.gov/cdrh_docs/pdf4/H040006b.pdf. Accessed June 20, 2023.
59. Dowling RD, Gray LA, Etoch SW, et al. Initial experience with the AbioCor implantable replacement heart system. *J Thorac Cardiovasc Surg*. Jan 2004; 127(1): 131-41. PMID 14752423
60. Torregrossa G, Morshuis M, Varghese R, et al. Results with SynCardia total artificial heart beyond 1 year. *ASAIO J*. 2014; 60(6): 626-34. PMID 25158888
61. Romeo F, Acconcia MC, Sergi D, et al. Percutaneous assist devices in acute myocardial infarction with cardiogenic shock: Review, meta-analysis. *World J Cardiol*. Jan 26 2016; 8(1): 98-111. PMID 26839661
62. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. *Am Heart J*. Sep 2006; 152(3): 469.e1-8. PMID 16923414
63. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. *J Am Coll Cardiol*. Nov 04 2008; 52(19): 1584-8. PMID 19007597

64. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. *Eur Heart J*. Jul 2005; 26(13): 1276-83. PMID 15734771
65. Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. *J Am Coll Cardiol*. Jan 24 2017; 69(3): 278-287. PMID 27810347
66. Karami M, Eriksen E, Ouweneel DM, et al. Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. *Eur Heart J Acute Cardiovasc Care*. Dec 06 2021; 10(9): 1009-1015. PMID 34327527
67. Schrage B, Ibrahim K, Loehn T, et al. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. *Circulation*. Mar 05 2019; 139(10): 1249-1258. PMID 30586755
68. Sieweke JT, Berliner D, Tongers J, et al. Mortality in patients with cardiogenic shock treated with the Impella CP microaxial pump for isolated left ventricular failure. *Eur Heart J Acute Cardiovasc Care*. Mar 2020; 9(2): 138-148. PMID 29405734
69. Schäfer A, Werner N, Burkhoff D, et al. Influence of Timing and Predicted Risk on Mortality in Impella-Treated Infarct-Related Cardiogenic Shock Patients. *Front Cardiovasc Med*. 2020; 7: 74. PMID 32478095
70. Griffith BP, Anderson MB, Samuels LE, et al. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. *J Thorac Cardiovasc Surg*. Feb 2013; 145(2): 548-54. PMID 22405676
71. Lemaire A, Anderson MB, Lee LY, et al. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. *Ann Thorac Surg*. Jan 2014; 97(1): 133-8. PMID 24090575
72. Lauten A, Engström AE, Jung C, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. *Circ Heart Fail*. Jan 2013; 6(1): 23-30. PMID 23212552
73. Ouweneel DM, de Brabander J, Karami M, et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. *Eur Heart J Acute Cardiovasc Care*. Jun 2019; 8(4): 338-349. PMID 30403366
74. Ait Ichou J, Larivée N, Eisenberg MJ, et al. The effectiveness and safety of the Impella ventricular assist device for high-risk percutaneous coronary interventions: A systematic review. *Catheter Cardiovasc Interv*. Jun 2018; 91(7): 1250-1260. PMID 28941078
75. Briasoulis A, Telila T, Palla M, et al. Meta-Analysis of Usefulness of Percutaneous Left Ventricular Assist Devices for High-Risk Percutaneous Coronary Interventions. *Am J Cardiol*. Aug 01 2016; 118(3): 369-75. PMID 27265673
76. O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. *Circulation*. Oct 02 2012; 126(14): 1717-27. PMID 22935569
77. Reddy YM, Chinitz L, Mansour M, et al. Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. *Circ Arrhythm Electrophysiol*. Apr 2014; 7(2): 244-50. PMID 24532564
78. Aryana A, Gearoid O'Neill P, Gregory D, et al. Procedural and clinical outcomes after catheter ablation of unstable ventricular tachycardia supported by a percutaneous left ventricular assist device. *Heart Rhythm*. Jul 2014; 11(7): 1122-30. PMID 24732372
79. Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. *J Am Coll Cardiol*. Feb 08 2011; 57(6): 688-96. PMID 20950980
80. Kirklin JK, Pagani FD, Goldstein DJ, et al. American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. *J Heart Lung Transplant*. Mar 2020; 39(3): 187-219. PMID 31983666
81. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. Aug 08 2017; 136(6): e137-e161. PMID 28455343

82. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Oct 15 2013; 62(16): e147-239. PMID 23747642
83. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. May 03 2022; 145(18): e876-e894. PMID 35363500
84. Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. *Circulation*. Nov 27 2012; 126(22): 2648-67. PMID 23109468
85. Bernhardt AM, Copeland H, Deswal A, et al. The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support. *J Heart Lung Transplant*. Apr 2023; 42(4): e1-e64. PMID 36805198
86. Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. *J Am Coll Cardiol*. May 19 2015; 65(19): e7-e26. PMID 25861963
87. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Ventricular Assist Devices (20.9.1). 2020; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=360&ncdver=2&keyword=ventricular%20assist&keywordType=starts&areald=all&docType=NCD&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAA&KeyWordLookUp=Doc&KeyWordSearchType=Exact>. Accessed June 20, 2023.